These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

The bioengineered protein drugs market is experiencing a paradigm shift, with pharmaceutical and biotech companies leveraging advanced biopharmaceuti ...

The platform achieves titers of more than 15 g/L for non-monoclonal antibody recombinant proteins ... These include nanobodies, enzymes, antibody fragments, cytokines, pDNA, antigens and polypeptides, ...

and recombinant PD-L1-Fc protein was evaluated in DSS-treated wild-type and Rag-1 knockout (KO) mice. We examined differentiation of T-helper cells, frequency of innate immune cells, and cytokine ...

Stem cells can self-renew and differentiate, with potential for treating diseases like cancer and heart disease. Cytokines ...

Cytokine-enhanced systems provide valuable platforms for drug screening, toxicity testing ... Additionally, the high cost and batch variability of recombinant cytokines remain barriers to widespread ...

February 19, 2025--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access ...

As a global leader in life science reagents, Sino Biological offers a comprehensive panel of recombinant cytokines and growth factors characterized by validated bioactivity, batch-to-batch consistency ...

4 Moreover, recombinant cytokines' elevated cost and batch variability ... place as critical tools in the ongoing transformation of drug discovery and regenerative medicine. Figure 2.